The content on this site is intended for healthcare professionals only
Dr Pantziarka speaks with ecancertv at ESMO 2016 about current efforts, and regulatory hurdles, towards the repurposing of medicines that are approved to treat other diseases, but have the potential to improve cancer patient outcomes.
He discusses how propranolol, a beta-blocker commonly prescribed to treat hypertension, might be a cheap and effective adjuvant in cancer therapy.
Dr Pantziarka is also joined by Dr Lydie Meheus of The Anticancer Fund, Belgium.
Read Dr Pantziarka and Dr Meheus’ article Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent here.
Drug repurposing was discussed further at a joint meeting of the BACR and ECMC, reported by ecancer here.
Prostate cancer
Enhancing head and neck oncology: Key insights from the conference
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 4th - 10th, 2023
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
